Mad Titan

OvaScience: Still On The Sidelines Because Of The "Minimal Manipulation" Controversy

This is a myopic piece, focused on a regulatory issue and targeted toward investors who may be long the stock or otherwise following OvaScience (NASDAQ:OVAS). That is to say that I won't be discussing, except where highly relevant, the other issues surrounding the stock and its next-generation technologies for improving in vitro fertilization (IVF). For investors who are less familiar with the story and want to get up to speed, I refer you to a recent SA article by a long investor, which covers much of the basics, as well as initiation reports by sell-side analysts.

The pertinent background is that OVAS has been developing the science of using a patient's own mitochondria (the energy factories in our...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details